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The incidence of gastro-oesophageal junction (GEJ) adenocarci-
noma has markedly increased over the last 20–30 years (Blot et al,
1991; Powell and McConkey, 1992; Pera et al, 1993). This
contrasts with the decreased incidence of carcinoma of the distal
stomach both in Western countries and Japan (Sons and Borchard,
1986; Paterson et al, 1987). Despite improvements in early
diagnosis and therapy, the prognosis of GEJ adenocarcinoma
remains poor due to the fact that metastasis is already present in
most patients at diagnosis (Wang et al, 1993; Jakl et al, 1995).
Multimodality treatments have not yet exerted a significant impact
on long-term survival, which remains at about 10% at 5 years
(MacFarlane et al, 1988; Wolfe et al, 1988; Ohno et al, 1995).
Until recently, most researchers thought of all GEJ adeno-
carcinoma as an anatomical variety of either distal-oesophageal or
gastric adenocarcinoma (Webb and Busuttil, 1978; Bosh et al,
1979; Wang et al, 1986; Stemmermann et al, 1994). Siewert and
Stein (1996) have underlined the clinical importance of distin-
guishing true carcinoma of the cardia arising from epithelium of
the GEJ, when the tumour centre is located within 1 cm oral or 
2 cm aboral of the anatomical GEJ (type II in their classification),
from those originating either in the distal oesophagus (i.e. from
Barrett’s oesophagus) (type I) or from subcardial gastric mucosa
(type III).
Many studies have evidenced the importance of proliferative
rate, p53 mutation (evidenced by its overexpression) in the
progression of adenocarcinomas of the stomach and distal oesoph-
agus (Casson et al, 1991; Imazeki et al, 1992; Wang et al, 1994): in
particular, p53 mutation or protein aberrancy has been correlated
with tumour development, invasiveness and poor prognosis
(Martin et al, 1992; Wang et al, 1994; Moskaluk et al, 1996; Wu et
al, 1998). Transforming growth factor a (TGF-a) has been shown
to be an important proliferation activator in various types of
epithelial tissue (Malden et al, 1989; Derynk, 1988). Normal
gastric mucosa has been shown to express significantly lower
levels of TGF-a protein with respect to mucosa adjacent to gastric
carcinomas, metaplastic intestinalized mucosa and gastric carci-
nomas, particularly of the intestinal type (Nasim et al, 1992; Filipe
et al, 1995). Advanced gastric carcinomas expressing high levels
of both TGF-a protein and epidermal growth factor receptor 
show a worse prognosis (Yonemura et al, 1992). Furthermore, in
patients with oesophageal squamous carcinoma, TGF-a expres-
sion has been found to correlate with poor prognosis (Iihara et al,
1993). Sauter et al (1995) found that persistence of (or a rise in)
TGF-a protein in adenocarcinomas of the distal oesophagus after
treatment with high-dose radiation therapy and chemotherapy
correlated with worse prognosis. In contrast, in preoperative
colorectal carcinoma biopsies, Younes et al (1996) found that high
expression of TGF-a protein is a good prognostic indication. On
the other hand, De Jong et al (1998) have reported that TGF-a
expression in resected liver metastases from colorectal adenocarci-
noma is associated with unfavourable prognosis. These discrepan-
cies prompted us to examine the histological material from 87 type
II GEJ adenocarcinomas and their metastatic lymph nodes to
investigate how TGF-a mRNA (and its protein) and p53 over-
expression correlate with the biological and clinical behaviour of
this tumour type.
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Summary The incidence of gastro-oesophageal junction (GEJ) adenocarcinoma is increasing in Western countries and prognosis is poor
since metastasis is most often present at diagnosis. We examined samples from 87 resected type II GEJ adenocarcinomas, 30 of these with
endoscopic diagnostic biopsy material, to evaluate transforming growth factor alpha (TGF-a) expression and p53 overexpression by
immunohistochemistry and in situ hybridization (for TGF-a), in relation to biological and clinical behaviour. TGF-a messenger RNA (mRNA)
and protein were detectable in neoplastic cells in 56% and 64% cases respectively. TGF-a mRNA was detected in intra- and peritumoral
lymphocytes and those of metastatic lymph nodes. TGF-a protein expression was significantly associated with tumour progression 
(P = 0.025) and lymph node metastasis (P < 0.05). The strong TGF-a expression found in neoplastic cells inside blood and lymphatic vessels
and in metastatic localizations suggests that TGF-a-positive GEJ adenocarcinomas could have a more aggressive biological phenotype. The
expression of TGF-a mRNA and protein in both inflammatory and neoplastic cells indicates that TGF-a is directly synthesized by both cell
compartments. Finally, since TGF-a expression was associated with lymph node metastasis, its detection in preoperative perendoscopic
biopsies might identify patients with more aggressive tumours who may need additional therapy, including neo-adjuvant treatment. © 2000
Cancer Research Campaign
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Patients and histological samples
Surgical specimens were studied of GEJ adenocarcinoma, type II
according to Siewert and Stein’s classification (1996) from 
87 patients (20 females, 67 males, mean age 62 years) who under-
went total gastrectomy, distal oesophagectomy and extended
lymphadenectomy at the Surgical Department of our institution
between 1972 and 1996 and had a minimum survival of 2 months
(max. 166 months, mean 33 months). In all cases, a radical resec-
tion was macroscopically achieved, as evaluated on intraoperative
frozen sections. None of the patients had a significant history 
of gastro-oesophageal reflux. In 30 cases, the preoperative 
biopsy was performed in our institution, and diagnostic material
was available for study by immunohistochemistry and in situ
hybridization. Gastric, cardiac and oesophageal samples were
taken from each specimen. Foci of intestinal metaplasia were
never observed in the oesophageal mucosa. The point of maximum
infiltration was sampled in each case. Multiple samples were
always taken of the apparently unaffected surrounding gastric and
oesophageal tissues. In the absence of a separate staging classifica-
tion for GEJ adenocarcinoma, American Joint Cancer Committee
(AJCC) guidelines for gastric cancer were employed. Accordingly,
one patient was classified as stage pT1, 10 were pT2 and 76 were
pT3–4. In 28 patients there was no metastatic spread to the lymph
nodes, while 35 were N1 and 24 were N2, of whom two were M1
(Table 1). The neoplasms were well to moderately differentiated
(G1–2) in 22 patients, poorly differentiated (G3) in 44 patients and
undifferentiated (G4) in 21 patients (AJCC criteria). Tissues were
fixed in formalin for a maximum of 24 h at 4°C. Fixed material
was then processed through absolute ethanol and Histo-clear
(histological clearing agent, Atlanta, GA, USA), and paraffin
embedded at 58°C in Paraplast Plus (Sherwood Medical, Athy,
Ireland) for a maximum of 2 h. Serial 4-mm thick sections were cut
from each block, collected on silane precoated slides and allowed
to dry overnight at 37°C prior to use. One section of each sample
was stained with H&E.
Immunohistochemistry procedures
Sections were dewaxed and rehydrated through alcohol series up
to distilled water. The endogenous peroxidase activity was
suppressed by a 0.3% solution of hydrogen peroxide (H2O2) in
methanol for 20 min. After two washes in Tris buffer saline (TBS),
sections to be incubated with the anti-human TGF-a monoclonal
antibody (mAb) (clone 213–4.4, Calbiochem, Cambridge, MA,
USA) diluted 1:100 were processed in a microwave oven in EDTA
1m M, pH 8 for two cycles of 5 min each. Sections to be incubated
with mAb anti-p53 (clone DO-7 Dako, Glostrup, Denmark)
diluted 1:80 and polyclonal antibody (pAb) anti-Ki-67 antigen
(Dako) diluted 1:50 were processed in a microwave oven in citrate
buffer (10 mM, pH 6) for 4 cycles of 5 min. All sections were incu-
bated overnight at 4°C in a humidified chamber. After 
3 rinses in TBS, the tissue samples were incubated with the 
mAb or pAb Envision Plus HRP system (Dako) for 30 min.
Immunological reactions were developed in 3,3¢-diaminobenzi-
dine (Sigma, St Louis, MO, USA) in TBS (0.6 mg ml–1),
containing 0.02% H2O2 for 5 min in the dark. The slides were then
counterstained with Mayer’s haematoxylin for 5 s, dehydrated and
mounted in Eukitt (O Kindler, Freiburg, Germany). Negative
controls were performed by substituting the specific primary anti-
body with non-immune serum.
Preparation of cRNA probes
The cDNA corresponding to human TGF-a, consisting of 930 bp
of the open reading frame of the gene, was sub-cloned in a pGem1
plasmid (2900 bp, Promega, Madison, WI, USA). The plasmid
was linearized either with EcoRI (Pharmacia Biotech, Uppsala,
Sweden) or HindIII (Gibco-BRL, Milan, Italy) and 1 mg was then
used as a template for in vitro synthesis of the sense and antisense
probes respectively. Digoxigenin-labelled riboprobes were gener-
ated with either SP6 or T7 RNA polymerase (Roche Diagnostics,
Milano, Italia), for 2 h at 37°C in 1 3 transcription buffer, 35 U of
RNAase inhibitor, 1 mM each of ATP, CTP and GTP, as well as 1
mM of a mixture of cold 10 mM UTP and digoxigenin-UTP (6.5
and 3.5 mM respectively) (Roche). For each probe, the length was
reduced to a mean size of 50–100 nucleotides by means of alkaline
hydrolysis.
In situ hybridization
Formalin-fixed, paraffin-embedded sections were dewaxed, rehy-
drated and washed in phosphate-buffered saline (PBS). Sections
were digested with proteinase K (2.5 mg ml–1) (Sigma, St Louis,
MO, USA) in 50 mM Tris–HCl, 5 mM EDTA (pH 7.2) for 30 min at
37°C, fixed in 4% paraformaldehyde in PBS for 5 min at room
temperature, and then washed in PBS. Prior to hybridization,
sections were dehydrated and air dried. Hybridization was
performed at 42–43°C overnight by applying 80–100 ng of
digoxigenin-labelled probe in 25 ml of hybridization buffer (50%
deionized formamide, 2 ´ SSC (saline-sodium citrate), 10% dextran
sulphate, 1% w/v sodium dodecyl sulphate [SDS]) per section 
under a glass coverslip. Coverslips were then gently floated off in 
5 ´ SSC. The highest stringency of post-hybridization washes was
60°C in 50% deionized formamide-2 ´ SSC for 20 min. Sections
were rinsed again in 2 ´ SSC, 0.5 ´ SSC, 0.1 ´ SSC, for 
15 min each at 37°C, and then equilibrated in Buffer 1 (100 mM
Tris–HCl, 150 mM sodium chloride (NaCl) pH 7.5). Anti-
digoxigenin pAb antibody diluted 1:500 in Buffer 1 was applied
overnight at 4°C. Detection was accomplished with nitro-blue 
tetrazolium (340 mg ml–1)/5-bromo-4-chloro-3-indolyl-phosphate
(170 mg ml–1) (NBT/BCIP) for 6–8 h (Roche) in buffer 2 (100 mM
Tris–HCl, 50 mM magnesium chloride (MgCl2, pH 9.5) in the pres-
ence of 1 mM levamisole (Sigma). Each section was counterstained
in methyl green, dried at 42°C and glycerol mounted. Controls for
the specificity of in situ hybridization results were performed by: (1)
pretreatment of tissue sections with RNAase (100 mg ml–1) for 1 h
at 37°C, before hybridization; (2) hybridization with the TGF-a
sense probe; (3) hybridization with the buffer alone, without the
probe.
Statistical analysis
We analysed the clinical-pathological parameters (age, sex and
pathological stage) as well as the immunohistochemistry and in
situ hybridization results of the investigated markers (proliferative
rate, p53, TGF-a protein and transcripts), relating them to the clin-
ical outcome of the patients studied. Data analysis was performed
by the SPSS statistical package using Cox regression to study the
survival model.
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Presence of TGF-a transcripts was evidenced by in situ hybridiza-
tion in the basal layer of the oesophageal epithelium and in basal
cells of the gastric glands (both known to be in continuous renewal
because of normal turnover). TGF-a messenger RNA (mRNA)
was also detected in intra- and peritumoral lymphocytes and those
of metastatic lymph nodes. Only scattered positive lymphocytes
were detected in normal mucosa and in non-metastatic lymph
nodes. High amounts of the transcripts were observed in 49 (56%)
cases of adenocarcinoma. In particular, TGF-a mRNA was
detected in the majority of neoplastic cells arranged singly or in
strings along the line of tumour invasion (Figure 1 A,B) and in the
lymphatic or blood vessels. The metastatic lymph-node cells also
expressed TGF-a transcripts. TGF-a protein expression was intra-
cytoplasmic and diffuse in the neoplastic cells of 56 (64%) cases
(Figure 1C). Co-localization of TGF-a mRNA and protein was
nearly always found both in neoplastic cells and in lymphocytes.
In seven cases TGF-a protein was present in the absence of its
mRNA even in the basal layer of the oesophageal mucosa, almost
certainly due to the inevitable degradation of TGF-a mRNA in the
oldest archival materials.
Overexpression of p53 protein (Figure 2) was strictly confined to
the nuclei of the majority of neoplastic cells of 61/87 (70%) cases
(Table 2). Particularly, marked staining for p53 was detected in
poorly or undifferentiated carcinomas and in ones with an infiltrating
pattern along the oesophageal and gastric walls or with extensive
invasion of the submucosa. Furthermore, neoplastic elements in
metastatic lymph nodes also showed clear p53 immunoreactivity.
The proliferative index of the neoplasms, as evaluated with the
Ki-67 pAb, was scored < 10% in 30 (34%) cases and > 10% in 57
(66%) cases. A higher index was observed in poorly differentiated
tumours and in advanced tumour stage (Table 2). Ki-67 positivity
was also observed in the basal layer of the squamous epithelium of
the oesophagus and in intra- and peritumoral lymphocytes.
In the 30 preoperative biopsies under study, immunohistochem-
ical analysis of p53 and TGF-a and in situ hybridization of TGF-a
mRNA showed similar sensitivity and specificity to the surgical
TGF-a in gastro-oesophageal junction carcinoma 867
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Figure 1 (A) Neoplastic glands and surrounding lymphocytes alongside the
invasive front of a GEJ adenocarcinoma show high levels of TGF-a mRNA by
in situ hybridization (NBT/AP staining). (B) Negative control on the same
case using the TGF-a sense probe (NBT/AP staining); (C) Neoplastic cells in
lymphatic and blood vessels of an infiltrating GEJ adenocarcinoma reveal
strong immunostaining using the anti TGF-a mAb (DAB staining)
C
B A
Figure 2 Immunohistochemical, nuclear localization of p53 protein in a
moderately differentiated GEJ adenocarcinoma (DAB staining)
Table 1 Pathological stage of 87 patients with GEJ adenocarcinoma
N0 N1 N2 Total cases
pT1 1 0 0 1
PT2 6 3 1 10
PT3–4 21 32 23 76samples. In particular, 22/30 preoperative biopsies showed diffuse
positivity both for TGF-aprotein and mRNA, while the remaining
eight cases were negative. This suggests that TGF-aprotein and
mRNA can both be confidently studied on preoperative endo-
scopic biopsy specimens.
Statistical analysis
Cox step-wise regression analysis of the variables (TNM, p53,
Ki67 and TGF-amRNA and protein) showed a significant rela-
tionship with increased mortality for p53 (P= 0.030) and N+ (P=
0.0025), while TGF-aprotein just missed significance (P= 0.095)
due to the masking effect of the variable N+; in effect, logistic
regression demonstrated a significant relationship between TGF-a
protein and N+ (P= 0.05). When N+ was excluded from the Cox
regression, the significant variables were p53 (P= 0.039) and
TGF-aprotein (P= 0.024); TGF-amRNA expression failed to
reach significance only because of the seven cases that appeared
negative due to degradation. Logistic regression also showed that
TGF-aprotein was significantly associated with tumour progres-
sion (i.e. TNM) (P= 0.025). Clinical outcome was not influenced
by sex, age or histological grade.
DISCUSSION
The present study suggests that detection of TGF-aexpression is
of clinical relevance in type II GEJ adenocarcinomas, as defined
by Siewert and Stein (1996), and also sheds new light on the
biological action of this growth factor.
On clinical grounds, current issues regarding the treatment of
type II GEJ adenocarcinoma include the role of surgery, selection
of candidates and the aims of the different operative procedures
employed (Sharpe, 1996). Reports from China and Japan have
revealed good long-term survival only in patients surgically
resected for stage I. Unfortunately, in the USA and Western
Europe, even when early diagnosis is made patients are usually
already in stage II or III and the modalities of treatment are still
undefined.
Activation or suppression of oncogenes and anti-oncogenes has
consistently been found to correlate with tumour progression and
biological aggressiveness. Expression of their protein products as
evaluated on endoscopic biopsy sections can provide useful indica-
tions for therapy. In particular, p53 overexpression is known to be a
reliable marker of poor prognosis in oesophageal adenocarcinomas
(Casson et al, 1995; Patel et al, 1997). As expected, in our series,
p53 overexpression correlated negatively with survival (P= 0.030).
Its persistence during neoplastic progression and its prognostic
significance are thought to be related to a situation of genetic insta-
bility associated with the activation of other oncogenes or growth
factors (Hartwell, 1992; Wu et al, 1998), including TGF-a.
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Figure 3 Cumulative survival for patients with GEJ adenocarcinoma
according to TGF-aprotein expression (A), p53 nuclear accumulation (B)
and presence of lymph-node metastases (C). Clinical outcome is markedly
influenced by TGF-aexpression (P = 0.0235), p53 accumulation (P =
0.0392) and N stage (P = 0.0025)
Table 2Biological findings of 87 patients with GEJ adenocarcinoma
No. of TGF-aTGF-amRNA p53 Ki67>10%Ki67<10%
cases
pT1 1 0 0 0 1 0
PT2 10 5 (50%) 3 (30%) 5 (50%) 6 (60%) 4 (40%)
PT3–4 76 51 (67%) 46 (52%) 56 (74%) 50 (66%) 26 (34%)
Total 87 56 (64%) 49 (56%) 61 (70%) 57 (66%) 30 (34%)We found a negative relationship between TGF-a protein and
survival (P = 0.024) when the masking effect of N was excluded,
suggesting that TGF-a detection could be of prognostic value in
type II GEJ adenocarcinomas. Our series confirms the precedence
of tumour stage and lymph-node metastasis as overall prognostic
indicators, as in most malignancies (Sharpe and Moghissi, 1996;
Steup et al, 1996; Kajiyama et al, 1997). However, in Western
countries GEJ adenocarcinomas are generally diagnosed in a rela-
tively late stage due to the lack of early signs or symptoms and the
tumour’s aggressive biological behaviour. Furthermore, clinical
staging does not always correspond to the pathological stage of the
process, which can be evaluated only after surgery. Thus, biolog-
ical markers that can provide therapeutic indications at the time of
endoscopic biopsy may be especially welcome for GEJ adeno-
carcinoma patients.
Immunohistochemical assessment of p53 protein overexpres-
sion seems to be the most important current biological prognostic
marker in GEJ adenocarcinomas. However, evaluation of p53
tumour-suppressor gene mutations (rather than indirect immuno-
histochemical assessment of the protein accumulation) would
require DNA sequencing after single-strand conformational poly-
morphism polymerase chain reaction (SSCP-PCR). In certain
cases, this distinction has been found to be important (Coggi et al,
1997). Thus, we think that TGF-a expression may provide further
information on the biological behaviour of type II GEJ adeno-
carcinomas that could be useful for clinical management.
In our study, expression of TGF-a mRNA and its protein product
were detectable in the neoplastic cells in 56% and 64% of cases,
respectively, as well as within the blood and lymphatic vessels and
in the metastatic lymph nodes, suggesting that neoplastic cells
which express TGF-a have a more aggressive biological pheno-
type. This could be due either to: (1) a direct chemotactic effect of
TGF-a; (2) interaction of TGF-a with other growth factors or adhe-
sion molecules; (3) a possible role of TGF-a in the induction of
angiogenesis within the tumour, as previously suggested (Schreiber
et al, 1986; Cai et al, 1997); (4) concomitant autocrine controlled
proliferation and protection from apoptosis (Foster et al, 1999).
Interestingly, in adenocarcinomas of the distal oesophagus, Sauter
et al (1995) have shown that persistent or increased expression of
TGF-a after neo-adjuvant therapy is related to poor prognosis.
Taken together, these observations make us think that in type II GEJ
adenocarcinomas TGF-a detection at endoscopic biopsies taken
before and after neoadjuvant treatment might provide important
therapeutic indications, independently of TNM.
From the biological standpoint, we were interested to find that
the lymphocytes in and around the tumour and in the metastatic
lymph nodes also strongly expressed TGF-a mRNA and protein.
Recent studies have shown that in several non-neoplastic intestinal
pathologies, the inflammatory component is capable of activating
growth factors that stimulate epithelial proliferation, thereby
inducing crypts hyperplasia (Bajaj-Elliott et al, 1998). Other
studies have focused on the role of the inflammatory component
and its prognostic significance in different malignant tumours,
along with the mechanism by which some cytokines can either
encourage or inhibit tumour growth (Ropponen et al, 1997; Naito
et al, 1998). Our observation of co-localization of TGF-a mRNA
and protein in both inflammatory and neoplastic cells indicates
that TGF-a is directly synthesized by both cell compartments.
Moreover, the strong TGF-a expression in neoplastic cells within
blood vessels at the edge of the tumours seems to support the
hypothesis that production of this protein is associated with
tumour progression.
In conclusion, we would like to propose detection of TGF-a
protein expression as a new marker to help predict the biological
behaviour of type II GEJ adenocarcinomas at the time of endo-
scopic biopsy and decide on their clinical management. On biolog-
ical grounds, we think that TGF-a may exert its biological effect by
a dual autocrine/paracrine mechanism. This invites further investi-
gation on the role of TGF-a in other epithelial malignancies.
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